Phase 2RecruitingAge-related condition
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
- Sponsor
- Edgewise Therapeutics, Inc. (Industry)
- Enrolment
- 90 planned
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- EDG-15400 25 mg; Placebo to match EDG-15400 25 mg or 50 mg; EDG-15400 50 mg
- Ages
- adults, older adults
- Registry
- NCT07795814
Full record on ClinicalTrials.gov
From the registry
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
Primary outcomes
- Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
History
Primary completion expected
Last registry update
Registered
Started